Pharma

Clinical trial software partnership forged for more efficient data tracking

Two software companies that track documents and data for clinical trials have forged a partnership to cut the amount of time it takes life science firms to submit applications for approval from the U.S. Food and Drug Administration. The move, said a spokesman for BioClinica Partners, was spurred by BioClinica and NextDoc‘s customers. Newtown, Pennsylvania-based […]

Two software companies that track documents and data for clinical trials have forged a partnership to cut the amount of time it takes life science firms to submit applications for approval from the U.S. Food and Drug Administration.

The move, said a spokesman for BioClinica Partners, was spurred by BioClinica and NextDoc‘s customers.

Newtown, Pennsylvania-based BioClinica’s system helps clinical trial sponsors and clinical research organizations to efficiently track, share and analyze data using SharePoint. NextDocs in King of Prussia, Pennsylvania also uses SharePoint to help provide a document repository for customers to provide easy access to essential trial documentation, according to a press statement.

In a phone interview with MedCity News, Stephen Boccardo of BioClinica said the partnership would help companies create a more efficient way to track their documents and data for clinical trials, effectively shaving months of time from the process.

“A lot of documentation is scanned or in paper format and it can be tough for companies because there is no one place to go [to track] that information … if you lose a copy,” Boccardo said. “With this system you can.”

Boccardo added that smaller biotechnology companies could benefit from the collaboration. “We actually see a need for biotechnology companies where they might have only one or two clinical studies going on, but they are multinational studies that run several years — that can be very difficult to track and maintain because they have a variety of parts.”

The collaboration between BioClinica and NextDoc was willed by its customers Boccardo said, in what looks to be a relatively new trend in the life science e-clinical technology space.